- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 847670, 6 pages
Abnormal Nerve Conduction Study Findings Indicating the Existence of Peripheral Neuropathy in Multiple Sclerosis and Neuromyelitis Optica
Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai Fuchu, Tokyo 183-0042, Japan
Received 23 April 2013; Accepted 21 September 2013
Academic Editor: Michael Mahler
Copyright © 2013 Yoko Warabi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- I. Sarova-Pinhas, A. Achiron, R. Gilad, and Y. Lampl, “Peripheral neuropathy in multiple sclerosis: a clinical and electrophysiologic study,” Acta Neurologica Scandinavica, vol. 91, no. 4, pp. 234–238, 1995.
- S. Misawa, S. Kuwabara, M. Mori, S. Hayakawa, S. Sawai, and T. Hattori, “Peripheral nerve demyelination in multiple sclerosis,” Clinical Neurophysiology, vol. 119, no. 8, pp. 1829–1833, 2008.
- C. Kamm and U. K. Zettl, “Autoimmune disorders affecting both the central and peripheral nervous system,” Autoimmunity Reviews, vol. 11, no. 3, pp. 196–202, 2012.
- T. Fukazawa, S. Kikuchi, R. Miyagishi et al., “CSF pleocytosis and expansion of spinal lesions in Japanese Multiple sclerosis with special reference to the new diagnostic criteria,” Journal of Neurology, vol. 252, no. 7, pp. 824–829, 2005.
- V. A. Lennon, T. J. Kryzer, S. J. Pittock, A. S. Verkman, and S. R. Hinson, “IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel,” Journal of Experimental Medicine, vol. 202, no. 4, pp. 473–477, 2005.
- T. Misu, K. Fujihara, A. Kakita et al., “Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis,” Brain, vol. 130, no. 5, pp. 1224–1234, 2007.
- Y. Aimoto, K. Ito, F. Moriwaka, K. Tashiro, and K. Abe, “Demyelinating peripheral neuropathy in Devic disease,” Japanese Journal of Psychiatry and Neurology, vol. 45, no. 4, pp. 861–864, 1991.
- M. Kitada, H. Suzuki, J. Ichihashi, R. Inada, K. Miyamoto, T. Takahashi, et al., “Acute combined central and peripheral demyelination showing anti-aquaporin 4 antibody positivity,” Internal Medicine, vol. 51, pp. 2443–2447, 2012.
- Y. Warabi, K. Yagi, and H. Hayashi, “Multiple sclerosis in Tokyo Metropolitan Neurological Hospital: from the view points of north latitude and Japan's rapid economic growth,” Clinical Neurology, vol. 43, no. 7, pp. 432–433, 2003.
- C. H. Polman, S. C. Reingold, B. Banwell et al., “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria,” Annals of Neurology, vol. 69, no. 2, pp. 292–302, 2011.
- D. M. Wingerchuk, V. A. Lennon, S. J. Pittock, C. F. Lucchinetti, and B. G. Weinshenker, “Revised diagnostic criteria for neuromyelitis optica,” Neurology, vol. 66, no. 10, pp. 1485–1489, 2006.
- D. M. Wingerchuk, V. A. Lennon, C. F. Lucchinetti, S. J. Pittock, and B. G. Weinshenker, “The spectrum of neuromyelitis optica,” The Lancet Neurology, vol. 6, no. 9, pp. 805–815, 2007.
- P. Y. Van den Bergh, R. D. Hadden, P. Bouche et al., “European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society: first Revision,” Journal of the Peripheral Nervous System, vol. 15, no. 1, pp. 1–9, 2010.
- K. Ota, M. Matsui, E. L. Milford, G. A. Mackin, H. L. Weiner, and D. A. Hafler, “T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis,” Nature, vol. 346, no. 6280, pp. 183–187, 1990.
- M. Pette, K. Fujita, D. Wilkinson et al., “Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 20, pp. 7968–7972, 1990.
- R. A. C. Hughes, D. Allen, A. Makowska, and N. A. Gregson, “Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy,” Journal of the Peripheral Nervous System, vol. 11, no. 1, pp. 30–46, 2006.
- B. C. Kieseier, M. C. Dalakas, and H.-P. Hartung, “Immune mechanisms in chronic inflammatory demyelinating neuropathy,” Neurology, vol. 59, no. 12, pp. S7–S12, 2002.
- M. Falcone, A. Scalise, C. Minisci, D. Romito, I. Cancelli, and G. L. Gigli, “Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy,” Neurological Sciences, vol. 27, no. 1, pp. 58–62, 2006.
- J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983.
- Y. Warabi, K. Yagi, H. Hayashi, and Y. Matsumoto, “Characterization of the T cell receptor repertoire in the Japanese neuromyelitis optica: T cell activity is up-regulated compared to multiple sclerosis,” Journal of the Neurological Sciences, vol. 249, no. 2, pp. 145–152, 2006.
- B. T. Sadatipour, J. M. Greer, and M. P. Pender, “Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis,” Annals of Neurology, vol. 44, no. 6, pp. 980–983, 1998.
- R. Srivastava, M. Aslam, S. R. Kalluri, L. Schirmer, D. Buck, B. Tackenberg, et al., “Potassium channel KIR4. 1 as an immune target in multiple sclerosis,” The New England Journal of Medicine, vol. 367, pp. 115–123, 2012.
- T. Berger, P. Rubner, F. Schautzer et al., “Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event,” The New England Journal of Medicine, vol. 349, no. 2, pp. 139–145, 2003.
- P. R. Burton, D. G. Clayton, L. R. Cardon et al., “Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls,” Nature, vol. 447, no. 7145, pp. 661–678, 2007.
- International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium, S. Sawcer, G. Hellenthal, M. Pirinen, C. C. Spencer, et al., “Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis,” Nature, vol. 476, pp. 214–219, 2011.
- N. A. Sutedja, H. G. Otten, E. A. Cats et al., “Increased frequency of HLA-DRB1*15 in patients with multifocal motor neuropathy,” Neurology, vol. 74, no. 10, pp. 828–832, 2010.
- M. Gironi, F. R. Guerini, E. Beghi et al., “HLA-DRB1 polymorphisms distribution in chronic dysimmune polyneuropathy,” Neuromuscular Disorders, vol. 18, no. 12, pp. 967–969, 2008.
- D. Ekstein, E. Linetsky, O. Abramsky, and D. Karussis, “Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis,” Neurology, vol. 65, no. 3, pp. 456–458, 2005.
- I. Pirko, N. L. Kuntz, M. Patterson, B. M. Keegan, B. G. Weinshenker, and M. Rodriguez, “Contrasting effects of IFNβ and IVIG in children with central and peripheral demyelination,” Neurology, vol. 60, no. 10, pp. 1697–1699, 2003.
- D. Matsuse, H. Ochi, K. Tashiro et al., “Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonβ-1b therapy in a patient with childhood-onset multiple sclerosis,” Internal Medicine, vol. 44, no. 1, pp. 68–72, 2005.
- R. Aronovich, A. Katzav, and J. Chapman, “The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally,” Clinical Reviews in Allergy and Immunology, vol. 42, pp. 181–188, 2012.
- E. Motta, A. Golba, M. Huc, and Z. Kazibutowska, “Development of Guillain-Barre syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate,” Polish Journal of Neurology and Neurosurgery, vol. 46, pp. 189–191, 2012.
- T. Yonekawa, T. Matsushita, M. Minohara et al., “T cell reactivities to myelin protein-derived peptides in neuromyelitis optica patients with anti-aquaporin-4 antibody,” Neurology Asia, vol. 16, no. 2, pp. 139–142, 2011.
- N. Matsuya, M. Komori, K. Nomura et al., “Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica,” International Immunology, vol. 23, no. 9, pp. 565–573, 2011.